MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
The company will license EGFR and cMet inhibitors from Celyn.
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
